Alnylam Pharmaceuticals, Inc.
ALNY
$473.29
$8.361.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 325.05% | -292.43% | 12.82% | 39.24% | -175.51% |
| Total Depreciation and Amortization | -1.28% | -7.06% | 6.57% | -8.11% | -40.58% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 164.16% | -5.12% | 78.68% | 13.65% | -38.33% |
| Change in Net Operating Assets | -598.92% | 230.57% | -100.12% | -239.25% | 60.70% |
| Cash from Operations | 643.84% | 23.82% | -45.14% | -217.71% | -87.84% |
| Capital Expenditure | -189.65% | -78.26% | 30.86% | 40.60% | 75.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 2,069.64% | -402.89% | 324.60% | 80.56% | -511.79% |
| Cash from Investing | 1,756.55% | -516.56% | 268.25% | 78.01% | -181.03% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -28.04% | -38.83% | 90.90% | 17.43% | 335.54% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -507.38% | -2,042.36% | -273.03% | -163.37% | -163.37% |
| Cash from Financing | -536.33% | -59.12% | 52.48% | -20.98% | 210.08% |
| Foreign Exchange rate Adjustments | -106.14% | 981.60% | 241.41% | -258.49% | 330.36% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 187.07% | -67.32% | 141.18% | 39.25% | -65.01% |